ELI LILLY $LLY Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $24.4B (Est. $22.61B) 🟢; +39% YoY 🔹 Adj. EPS: $7.48; +7% YoY 🔹 Gross Margin: 84.4% 🔹 Mounjaro Revenue: $10.7B; +65% YoY FY26 Guide: 🔹 Revenue: $91.0B-$92.0B (Est. $88.85B) 🟢; from $85B-$87B 🔹 EPS: $35.00-$36.00; from $35.50-$36.50 🔹 Performance Margin: 52.0%-52.5%; from 49.0%-50.5% 🔹 Tax Rate: 19%-20%; from 18%-19% Announcements: 🔹 Regulatory Progress: FDA approvals of Mounjaro, Onswik and Inluriyo; expanded Jaypirca indication 🔹 Pipeline: Phase 3 retatrutide and Ebglyss results; Phase 2 EloraTZP results; Phase 3 trials start in Q4 2026 Other Q3 Metrics: 🔹 Key Products Revenue: $17.1B 🔹 U.S. Revenue: $15.1B; +34% YoY 🔹 Outside U.S. Revenue: $9.3B; +47% YoY Key Updates: 🔹 Q3 Revenue Benefits: approximately $900M, incl. $410M Jardiance milestones 🔹 Acquired IPR&D: $4.2B charge; $4.57 EPS impact vs. $0.71 last year 🔹 Business Development: AtaiBeckley acquisition completed; Merida Biosciences acquisition completed after quarter end Comments: 🔸 “Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook,” 🔸 “Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience.”